Corcept Therapeutics (NASDAQ:CORT) Director G Leonard Baker, Jr. sold 30,000 shares of the business’s stock in a transaction dated Friday, May 11th. The shares were sold at an average price of $16.01, for a total transaction of $480,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Corcept Therapeutics opened at $17.61 on Wednesday, MarketBeat.com reports. Corcept Therapeutics has a 12 month low of $16.97 and a 12 month high of $17.90. The company has a market cap of $1.98 billion, a PE ratio of 33.00 and a beta of 1.92.
Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported $0.19 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.18 by $0.01. Corcept Therapeutics had a return on equity of 46.78% and a net margin of 75.05%. The business had revenue of $57.66 million during the quarter, compared to analysts’ expectations of $58.18 million. During the same quarter in the prior year, the business earned $0.06 earnings per share. The company’s quarterly revenue was up 108.9% compared to the same quarter last year. research analysts forecast that Corcept Therapeutics will post 0.73 EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in CORT. We Are One Seven LLC purchased a new position in Corcept Therapeutics in the fourth quarter worth $106,000. Tyers Asset Management LLC purchased a new position in Corcept Therapeutics in the first quarter worth $136,000. Asset Management One Co. Ltd. purchased a new position in Corcept Therapeutics in the first quarter worth $150,000. Riverhead Capital Management LLC purchased a new position in Corcept Therapeutics in the first quarter worth $155,000. Finally, Flinton Capital Management LLC purchased a new position in Corcept Therapeutics in the first quarter worth $173,000. Hedge funds and other institutional investors own 75.98% of the company’s stock.
About Corcept Therapeutics
Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression.
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.